Pathological changes caused by NAFLD are known to alter the expression and metabolic activity of CYP and UGT proteins [14], and represent an emerging important source of variability in drug exposure that is important to account for in drug development and the clinical use of medicines [15]. The gene discussed is SLC35A2; the disease is metabolic dysfunction-associated steatotic liver disease.